Curiox Biosystems (hereinafter ‘Curiox’), a company specializing in automated cell preprocessing equipment, received preliminary approval for KOSDAQ listing from the Korea Exchange on the 1st of this month.
Curiox plans to submit a securities registration statement within this month and proceed with the public offering process thereafter. The lead underwriter for the listing is Kiwoom Securities.
Curiox manufactures bio equipment that automates the cell analysis process, which is essential in new drug development or production. The company’s product, Laminar Wash equipment, is the only innovative device that automates the existing manual process and has been supplied to 18 out of the top 20 global biopharmaceutical companies.
Additionally, the company is the sole participant in the cell analysis process field within a consortium established by the U.S. National Institute of Standards and Technology together with cell gene therapy companies to set cell analysis standards. Through this, Laminar Wash is expected to be adopted as the standard method in the cell analysis process.
A Curiox representative stated, “Through the listing, we aim to realize the company’s vision of ‘leading the global automation platform for cell analysis’ and enhance the company’s competitiveness and financial stability.” He added, “We will diligently prepare for the listing process and make every effort to successfully register on the KOSDAQ market.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
